Heart failure is a growing global health challenge, yet significant gaps remain in its treatment. With millions of patients suffering from reduced quality of life and high mortality rates, there is an urgent need to innovate and transform care pathways.

In this episode, Dr. Ted Fjällman and Professor Lars Lund, discuss the critical gaps in the treatment of heart failure. They discuss recent advancements, the challenges facing patients and clinicians, and the potential for innovative therapies to transform care and improve outcomes for millions affected worldwide.

Professor Lund is a shareholder in AnaCardio.

The past few years have been challenging for many life science companies, both in the private setting but also those on public markets, and the IPO window for new listings has been essentially closed. The industry is dependent on the availability of capital as well as the risk appetite, both impacted by macroeconomic factors. Deal-making and M&A (merges and acquisitions) with pharma are the lifeblood of the industry.

In this episode, Ted Fjällman speaks to Tim Opler. Having taken part in more than 150 transactions with a total value of $100 billion, Tim shares his expertise and elaborates on different ways of financing innovation, a booming obesity field, and how patents are currently central to gaining a competitive advantage, but not the only measure.